Evidence map›Paper›PMID 40358163›Full record

ReviewCells2025

Role of IgG4 Antibodies in Human Health and Disease.

Li-Li Shi, Peng Xiong, Minglin Yang, Ozge Ardicli, Stephan Raphael Schneider, Anders Boutrup Funch, Ayca Kiykim, Juan Lopez, Cezmi A Akdis, Mübeccel Akdis

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Li-Li ShiSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7265 Davos, Switzerland.
Peng XiongSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7265 Davos, Switzerland.
Minglin YangSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7265 Davos, Switzerland.ORCID 0009-0002-7985-4537
Ozge ArdicliSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7265 Davos, Switzerland.ORCID 0000-0001-6077-0478
Stephan Raphael SchneiderSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7265 Davos, Switzerland.ORCID 0009-0004-6862-2735
Anders Boutrup FunchSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7265 Davos, Switzerland.ORCID 0000-0002-7576-3884
Ayca KiykimSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7265 Davos, Switzerland.
Juan LopezSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7265 Davos, Switzerland.
Cezmi A AkdisSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7265 Davos, Switzerland.
Mübeccel AkdisSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7265 Davos, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin G4 (IgG4), a unique subclass of IgG antibodies, plays diverse roles in human health and disease. Its distinct features, such as Fab-arm exchange and specific mutations, confer reduced effector functions compared to other IgG subclasses. In health, IgG4 responses contribute to immune tolerance, particularly in the context of allergen-specific immunotherapy (AIT), where they can mediate tolerance to environmental antigens, inhibit IgE-dependent mast cell degranulation, and compete with IgE for allergen binding. This helps in attenuating allergic symptoms and is associated with increased levels of allergen-specific IgG4. However, in disease scenarios, the role of IgG4 is complex. IgG4 lacks complement fixation and, thus, shows a reduced ability to activate immune effector pathways, it was initially thought to be protective against autoimmune diseases. However, emerging evidence suggests that it can contribute to pathology. For instance, IgG4 autoantibodies against specific antigens can aggravate conditions in certain autoimmune disorders. In some cancers, it may play a role in immune evasion, with higher levels correlating with poor patient survival, albeit in others, its exact function remains elusive. Overall, understanding the precise role of IgG4 in various physiological and pathological conditions is crucial for developing targeted therapeutic strategies and improving patient outcomes.

Indexed as

HealthImmunoglobulin GAnimalsAutoantibodiesAutoimmune DiseasesHumansAutoantibodiesImmunoglobulin Gallergen-specific immunotherapy (AIT)allergic diseaseautoimmune diseasechronic infectionIgG4immune tolerancetumor

Identifiers

PMID40358163
PMCPMC12071442

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.